- Home
- THRY vs IMNM Comparison
THRY vs IMNM Comparison
Compare THRY & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRY
- IMNM
- Stock Information
- Founded
- THRY 2003
- IMNM 2006
- Country
- THRY United States
- IMNM United States
- Employees
- THRY N/A
- IMNM N/A
- Industry
- THRY Industrial Machinery/Components
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- THRY Industrials
- IMNM Health Care
- Exchange
- THRY Nasdaq
- IMNM Nasdaq
- Market Cap
- THRY 703.2M
- IMNM 747.7M
- IPO Year
- THRY 2020
- IMNM 2020
- Fundamental
- Price
- THRY $15.30
- IMNM $12.01
- Analyst Decision
- THRY Strong Buy
- IMNM Strong Buy
- Analyst Count
- THRY 3
- IMNM 5
- Target Price
- THRY $24.33
- IMNM $28.60
- AVG Volume (30 Days)
- THRY 349.3K
- IMNM 803.1K
- Earning Date
- THRY 11-07-2024
- IMNM 11-13-2024
- Dividend Yield
- THRY N/A
- IMNM N/A
- EPS Growth
- THRY N/A
- IMNM N/A
- EPS
- THRY N/A
- IMNM N/A
- Revenue
- THRY $873,723,000.00
- IMNM $10,129,000.00
- Revenue This Year
- THRY N/A
- IMNM N/A
- Revenue Next Year
- THRY N/A
- IMNM N/A
- P/E Ratio
- THRY N/A
- IMNM N/A
- Revenue Growth
- THRY N/A
- IMNM N/A
- 52 Week Low
- THRY $13.06
- IMNM $7.76
- 52 Week High
- THRY $26.42
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- THRY 43.67
- IMNM 43.70
- Support Level
- THRY $15.00
- IMNM $12.99
- Resistance Level
- THRY $16.66
- IMNM $15.13
- Average True Range (ATR)
- THRY 0.62
- IMNM 0.93
- MACD
- THRY -0.06
- IMNM -0.16
- Stochastic Oscillator
- THRY 4.35
- IMNM 3.79
About THRY Thryv Holdings Inc.
Thryv Holdings Inc provides software as service (SaaS) management tools and digital and print marketing tools to small and mid-sized businesses. The company operates in four reportable segments namely Thryv U.S. Marketing Services, Thryv U.S. SaaS, Thryv International Marketing Services, and Thryv International SaaS. It generates maximum revenue from the Thryv U.S. Marketing Services segment.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.